Enboke Application Scope

Treatment of plaque-type (ordinary) psoriasis.
Treatment of subacute eczema/dermatitis.
More broadly: inflammatory skin diseases characterized by elevated IL‑8 in lesions.
enboke anti-human interleukin

Enboke Characteristics

Ingredients: Anti-Human Interleukin
Properties: Neutralizes IL‑8, inhibits neutrophil chemotaxis, reduces inflammation, scaling, and lesion symptoms
Packaging Specification: 10 g per tube (0.045 mg/g, equivalent to 45 µg per gram)
Storage: Store at 2 °C – 8 °C (refrigeration)
Expiry Date: 24 months from manufacture
Executive Standard: WS4-(S-012)-2004Z (China)
Approval Number: 国药准字S20030093
Date of Revision: Not publicly specified
Manufacturer: Dalian Yawei Pharmaceutical Co., Ltd.

Guidelines for the Use of Enboke

Dosage and Administration:
- Recommended Dose:
  - Max treated area: ≤ 20% body surface area.
  - Typical weekly total dose: 40–70 g (for psoriasis).
- Administration: Gently massage until fully absorbed.
- Missed Dose: Resume normal schedule; do not double dose.
Adverse Reactions:
- Common Adverse Reactions:
  - Local skin reactions: itching, burning sensation, redness—about 4% of plaque‑type psoriasis patients experienced such irritation in the first week; generally mild and did not affect continuation of treatment.
  - In a report with 113 subacute eczema patients, adverse reactions occurred in ~4.42%: mild to moderate itching, worsened pruritus, papules/pustules, erythema or aggravated erythema, local burning or pain; most resolved and did not preclude continued use.
- Serious Adverse Reactions:
  - No serious systemic adverse reactions publicly reported. According to available pharmacokinetic data, when applied topically, the antibody penetrates minimally; free antibody in blood and detectable anti-mouse antibodies (HAMA) were not found.
  - Long‑term safety data appears limited.
Contraindications:
- Allergy to Enboke or any cream component.
- Local or systemic active infection.
Precautions:
- Use with caution in patients with renal or cardiac dysfunction and pregnant or breastfeeding women.
- Observe for local allergic reactions, skin irritation. Discontinue if severe irritation occurs.
- Limit treated skin area to ≤ 20% body surface area.

Enboke Interactions

No public data about drug–drug interactions with Enboke cream. Because topical antibody penetration into systemic circulation is minimal and no systemic absorption was detected, systemic interactions are unlikely.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.